{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:20:14Z","timestamp":1780467614704,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Belimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is not a review focusing on all real-life experience with belimumab to date that could help to describe how this drug behaves in the Spanish clinical setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To describe the characteristics of SLE patients treated with belimumab added to standard of care in real-clinical setting in Spain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a comprehensive scoping review of real-world data (RWD) according to PRISMA Scoping Reviews Checklist and the framework proposed by Arksey and O\u2019Malley. PubMed and EMBASE were searched without language restriction and hand searches of relevant articles were examined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included data from 222 patients treated with belimumab for SLE included in 19 RWD studies conducted in Spain. The mean age was 40.9\u00a0years, 84.2% were female, and baseline scores SELENA-SLEDAI ranged between 5.9 and 12. Lupus nephritis basal prevalence was of 2.7%. The main reason for belimumab initiation was previous treatments lack of efficacy (69.7%) and the most common laboratory abnormalities were hypocomplementemia (40.9%), ANA\u2009+\u2009(34.2%), and anti-DNA (33.3%). The addition of belimumab to standard therapy was associated with a reduction of daily glucocorticoids intake in 1.4\u201311.1\u00a0mg at 6\u00a0months. Belimumab discontinuation was observed in 18.6% of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study helps to further explore the profile of SLE patients most likely to be treated with belimumab.<\/jats:p>\n              <jats:table-wrap><jats:table><jats:tbody>\n                    <jats:tr>\n                      <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>Scientific evidence in SLE provided by randomized controlled trials sometimes differs from the actual treatment of SLE patients in routine clinical practice.<\/jats:italic>\u2022 <jats:italic>There is a lack of published \u201creal-world\u201d data on SLE treatment with belimumab in Spain.<\/jats:italic>\u2022 <jats:italic>This scoping review intends to describe and analyze the clinical characteristics of SLE patients receiving belimumab in a real-life setting in Spain.<\/jats:italic>\u2022 <jats:italic>These \u201creal-world\u201d clinical experience can provide a more realistic view of the overall patterns of SLE care compared with clinical trials.<\/jats:italic><\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:sec>","DOI":"10.1007\/s10067-022-06287-9","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T19:02:50Z","timestamp":1658602970000},"page":"3373-3382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients"],"prefix":"10.1007","volume":"41","author":[{"given":"Carlos Rodr\u00edguez","family":"Escalera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6785-5677","authenticated-orcid":false,"given":"\u00c1ngela Mar\u00eda Zurita","family":"Guisado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Bahamontes-Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas Garc\u00eda","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"key":"6287_CR1","doi-asserted-by":"publisher","unstructured":"Yazdany J, Dall\u2019Era M (2018) Definition and classification of lupus and lupus-related disorders. Dubois\u2019 Lupus Erythematosus and Related Syndromes. Elsevier :15\u201322. https:\/\/doi.org\/10.1016\/B978-0-323-47927-1.00002-5","DOI":"10.1016\/B978-0-323-47927-1.00002-5"},{"issue":"5","key":"6287_CR2","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/MD.0b013e31822edf7f","volume":"90","author":"MD Alonso","year":"2011","unstructured":"Alonso MD, Llorca J, Martinez-Vazquez F et al (2011) Systemic lupus erythematosus in Northwestern Spain: a 20-year epidemiologic study. Med (Baltimore) 90(5):350\u2013358","journal-title":"Med (Baltimore)"},{"issue":"11","key":"6287_CR3","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1191\/0961203303lu469xx","volume":"12","author":"P L\u00f3pez","year":"2003","unstructured":"L\u00f3pez P, Mozo L, Guti\u00e9rrez C, Su\u00e1rez A (2003) Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. Lupus 12(11):860\u2013865","journal-title":"Lupus"},{"issue":"8","key":"6287_CR4","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/rheumatology\/keh238","volume":"43","author":"T Stoll","year":"2004","unstructured":"Stoll T (2004) Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus\u2013a 5-yr prospective study. Rheumatol 43(8):1039\u20131044. https:\/\/doi.org\/10.1093\/rheumatology\/keh238","journal-title":"Rheumatol"},{"issue":"4","key":"6287_CR5","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/acr.22173","volume":"66","author":"M Yurkovich","year":"2014","unstructured":"Yurkovich M, Vostretsova K, Chen W, Avi\u00f1a-Zubieta JA (2014) Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken) 66(4):608\u2013616. https:\/\/doi.org\/10.1002\/acr.22173","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"6287_CR6","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/art.40512","volume":"70","author":"EY Yen","year":"2018","unstructured":"Yen EY, Singh RR (2018) Brief report: lupus\u2014an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000\u20132015. Arthritis Rheumatol 70(8):1251\u20131255","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"6287_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/ard.2007.070367","volume":"67","author":"G Bertsias","year":"2008","unstructured":"Bertsias G, Ioannidis JPA, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67(2):195\u2013205","journal-title":"Ann Rheum Dis"},{"key":"6287_CR8","doi-asserted-by":"crossref","unstructured":"Oglesby A, Shaul AJ, Pokora T et al (2013) Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review. Int J Rheumatol 2013:1\u20139.http:\/\/www.hindawi.com\/journals\/ijr\/2013\/347520\/","DOI":"10.1155\/2013\/347520"},{"issue":"9","key":"6287_CR9","first-page":"1955","volume":"30","author":"DD Gladman","year":"2003","unstructured":"Gladman DD, Urowitz MB, Rahman P, Iba\u00f1ez D, Tam LS (2003) Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 30(9):1955\u20131959","journal-title":"J Rheumatol"},{"key":"6287_CR10","unstructured":"CHMP_Benlysta (2021) Annex i summary of product characteristics: belimumab. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/benlysta-epar-product-information_en.pdf. Accessed April 2021"},{"issue":"7","key":"6287_CR11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/14712598.2017.1324846","volume":"17","author":"V Tesar","year":"2017","unstructured":"Tesar V, Hruskova Z (2017) Belimumab in the management of systemic lupus erythematosus\u2013an update. Expert Opin Biol Ther 17(7):901\u2013908","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"6287_CR12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F et al (2020) Two-year randomized controlled trial of belimumab in lupus nephritis. N Engl J Med 383(12):1117\u20131128. https:\/\/doi.org\/10.1056\/NEJMoa2001180","journal-title":"N Engl J Med"},{"issue":"5","key":"6287_CR13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/rheumatology\/kep012","volume":"48","author":"MI Danila","year":"2008","unstructured":"Danila MI, Pons-Estel GJ, Zhang J, Vila LM, Reveille JD, Alarcon GS (2008) Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatol 48(5):542\u2013545. https:\/\/doi.org\/10.1093\/rheumatology\/kep012","journal-title":"Rheumatol"},{"issue":"9","key":"6287_CR14","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/art.24699","volume":"61","author":"DJ Wallace","year":"2009","unstructured":"Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT et al (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Care Res 61(9):1168\u20131178","journal-title":"Arthritis Care Res"},{"issue":"12","key":"6287_CR15","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, Cervera R et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918\u20133930","journal-title":"Arthritis Rheum"},{"issue":"9767","key":"6287_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721\u2013731","journal-title":"Lancet"},{"key":"6287_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/ar2506","volume":"10","author":"R Furie","year":"2008","unstructured":"Furie R, Stohl W, Ginzler EM et al (2008) Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 10:5","journal-title":"Arthritis Res Ther"},{"key":"6287_CR18","doi-asserted-by":"crossref","unstructured":"Doria A, Iaccarino L, Ghirardello A et al (2006) Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med119(8):700\u20136. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934306001938","DOI":"10.1016\/j.amjmed.2005.11.034"},{"issue":"7","key":"6287_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169(7):467. https:\/\/doi.org\/10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"issue":"1","key":"6287_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol Theory Pract 8(1):19\u201332","journal-title":"Int J Soc Res Methodol Theory Pract"},{"issue":"1","key":"6287_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1748-5908-5-69","volume":"5","author":"D Levac","year":"2010","unstructured":"Levac D, Colquhoun H, O\u2019Brien KK (2010) Scoping studies: advancing the methodology. Implement Sci 5(1):69. https:\/\/doi.org\/10.1186\/1748-5908-5-69","journal-title":"Implement Sci"},{"key":"6287_CR22","doi-asserted-by":"publisher","unstructured":"Cortes J, Marras C, Andreu JL, Calvo-Alen J, Garcia-Aparicio AM, Alvarez Diez E, et al (2014) Evolution of patients with systemic lupus erythematous treated with belimumab in clinical practice settings  (Observe Study). 2014 ACR\/ARHP Annu Meet S291.\u00a0https:\/\/doi.org\/10.1016\/j.jval.2014.08.1703","DOI":"10.1016\/j.jval.2014.08.1703"},{"issue":"Suppl 1","key":"6287_CR23","first-page":"A108","volume":"5","author":"MD la Navarro","year":"2018","unstructured":"la Navarro MD, R, Ar\u00e9valo K, Chalmeta I, et al (2018) PS7:147 Clinical experience of belimumab treatment in clinical practice of sle patients. Lupus Sci Med 5(Suppl 1):A108\u2013A108","journal-title":"Lupus Sci Med"},{"key":"6287_CR24","doi-asserted-by":"publisher","unstructured":"Navarro MD la R, Checa SC, Cort\u00e9s JI et al (2019) AB0463 belimumab iv effect in glucocorticoid treatment in systemic lupus erythematosus patients.  Annals of the Rheumatic Diseases 78(Suppl 2):1695.2\u20131696.\u00a0https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.6585","DOI":"10.1136\/annrheumdis-2019-eular.6585"},{"key":"6287_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.08.1703","author":"J Cort\u00e9s","year":"2019","unstructured":"Cort\u00e9s J, Andreu JL, Calvo J, Garc\u00eda-Aparicio AM, Coronell CG, D\u00edaz-Cerezo S (2019) Evaluation of use of belimumab in clinical practice settings (observe study) in Spain: health resource utilization and labour absenteeism. Value Health. https:\/\/doi.org\/10.1016\/j.jval.2014.08.1703","journal-title":"Value Health"},{"key":"6287_CR26","doi-asserted-by":"crossref","unstructured":"Carri\u00f3n-Barber\u00e0 I, Salman-Monte TC, Castell S, Castro-Dom\u00ednguez F, Ojeda F, Monfort J (2019) Successful treatment of systemic lupus erythematosus pleuropericarditis with belimumab: a case report and literature review. Eur J Rheumatol 1\u20133. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31329542","DOI":"10.5152\/eurjrheum.2019.17169"},{"issue":"2","key":"6287_CR27","first-page":"355","volume":"34","author":"C Gonzalez-Echavarri","year":"2016","unstructured":"Gonzalez-Echavarri C, Ugarte A, Ruiz-Irastorza G (2016) Rituximab-refractory lupus nephritis successfully treated with belimumab. Clin Exp Rheumatol 34(2):355\u2013356","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"6287_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0961203319835320","volume":"28","author":"AR Gim\u00e9nez","year":"2019","unstructured":"Gim\u00e9nez AR, Pastrana DB, Huaranga MAR et al (2019) Belimumab in refractory organizing pneumonia associated with systemic lupus erythematosus: a case report. Lupus 28(4):565\u2013568. https:\/\/doi.org\/10.1177\/0961203319835320","journal-title":"Lupus"},{"issue":"3","key":"6287_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/03009742.2016.1264626","volume":"46","author":"S Carbajal","year":"2019","unstructured":"Carbajal S, Zamora-Mart\u00ednez C, Prieto-Gonz\u00e1lez S, Quintana L, Espinosa G, Cervera R (2019) Systemic lupus erythematous exacerbation following cessation of belimumab treatment: comments on the article by Furer et al. Scand J Rheumatol 46(3):250\u2013251. https:\/\/doi.org\/10.1080\/03009742.2016.1264626","journal-title":"Scand J Rheumatol"},{"key":"6287_CR30","doi-asserted-by":"crossref","unstructured":"Husein-ElAhmed H, Callejas-Rubio J, Rios-Fernandez R, Ortego-Centeno N (2019) Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: a new anti-BLyS human monoclonal antibody. Indian J Dermatology, Venereol Leprol 80(5):477. http:\/\/www.ijdvl.com\/text.asp?2014\/80\/5\/477\/140335","DOI":"10.4103\/0378-6323.140335"},{"key":"6287_CR31","doi-asserted-by":"crossref","unstructured":"Castillo Dayer PV, Lozano Rivas N, Mart\u00ednez Ferr\u00edn JJ, Victoria Mart\u00ednez AM, S\u00e1nchez\u2010Pedre\u00f1o Guillen P, Marras Fern\u00e1ndez\u2010Cid C (2019) Belimumab treatment in rhupus: a case report with severe skin involvement. Dermatol Ther 32(5):e13056. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31393634","DOI":"10.1111\/dth.13056"},{"key":"6287_CR32","doi-asserted-by":"publisher","unstructured":"Moriano C, Garijo M, I\u00f1iguez C, et al (2018) AB0507 Belimumab in patients with systemic lupus erythematosus: outcomes in routine clinical practice. In: SLE, Sj\u00f6gren\u2019s and APS \u2013 treatment. BMJ Publishing Group Ltd and European League Against Rheumatism 77 (Suppl 2). 1413.1\u20131413. https:\/\/doi.org\/10.1136\/annrheumdis-2018-eular.7530","DOI":"10.1136\/annrheumdis-2018-eular.7530"},{"key":"6287_CR33","unstructured":"M Lorente XB y el grupo A-M (2018) Resultado a largo plazo del tratamiento peri\u00f3dico con Belimumab en pacientes con LES: datos de pr\u00e1ctica cl\u00ednica."},{"issue":"Suppl 2","key":"6287_CR34","doi-asserted-by":"publisher","first-page":"1074.1","DOI":"10.1136\/annrheumdis-2015-eular.3328","volume":"74","author":"D Hernandez-Fl\u03ccrez","year":"2015","unstructured":"Hernandez-Fl\u03ccrez D, Valor L, Del R\u00edo T et al (2015) AB0520 evaluating the effect of belimumab on clinical disease activity and B-cell in patients with systemic lupus erythematosus. Ann Rheum Dis 74(Suppl 2):1074.1-1074","journal-title":"Ann Rheum Dis"},{"key":"6287_CR35","unstructured":"Monserrat J, Perez A, Moruno H, et al (2016) Long term immunomodulatory effect in circulating B cell compartment of belimumab treated systemic lupus erythematosus patients. Clin Exp Rheumatol 34(4):S63. https:\/\/www.embase.com\/records?subaction=viewrecord&rid=1&page=1&id=L615008508"},{"issue":"Suppl 1","key":"6287_CR36","first-page":"A104","volume":"5","author":"V Aldasoro","year":"2018","unstructured":"Aldasoro V, Varela M, Mendizabal J, Garrido L, Fito C, del Val N, Guti\u00e9rrez R, Paniagua I, Horcada L, Ib\u00e1\u00f1ez R (2018) PS7:140 belimumab in systemic lupus erythematosus 1 year of follow up. Lupus Sci Med 5(Suppl 1):A104\u2013A105","journal-title":"Lupus Sci Med"},{"key":"6287_CR37","unstructured":"Riancho-Zarrabeitia L, Villa Blanco I, Santos-G\u00f3mez M, Aurrecoechea E (2018) Belimumab en lupus eritematoso sist\u00e9mico: experiencia en pr\u00e1ctica cl\u00ednica en un hospital comarcal. Reumatol Cl\u00ednica.https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X1830041X"},{"key":"6287_CR38","doi-asserted-by":"crossref","unstructured":"Argum\u00e1nez CM, Rusinovich O, Gir\u00e1ldez CR et al (2019) AB0475 belimumab: experience in clinical practice settings at a rheumatology department in a tertiary hospital. BMJ p. 1701.2\u20131702.","DOI":"10.1136\/annrheumdis-2019-eular.7989"},{"key":"6287_CR39","doi-asserted-by":"crossref","unstructured":"Anjo C, Mascar\u00f3 Jr J-M, Espinosa G, Cervera R (2019) Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting. Scand J Rheumatol 48(6):469\u201373. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31264525","DOI":"10.1080\/03009742.2019.1603324"},{"issue":"Suppl 1","key":"6287_CR40","doi-asserted-by":"publisher","first-page":"A71.3","DOI":"10.1136\/ejhpharm-2013-000436.176","volume":"21","author":"V Alonso Castro","year":"2019","unstructured":"Alonso Castro V, Gonzalez Martin C, Sanchez Guerrero A, TorralbaArranz A (2019) DI-005 use of belimumab for the treatment of systemic lupus erythematosus in a tertiary level hospital. Eur J Hosp Pharm 21(Suppl 1):A71.3-A72. https:\/\/doi.org\/10.1136\/ejhpharm-2013-000436.176","journal-title":"Eur J Hosp Pharm"},{"issue":"Suppl 1","key":"6287_CR41","doi-asserted-by":"publisher","first-page":"A2.3","DOI":"10.1136\/ejhpharm-2013-000436.6","volume":"21","author":"M AlmanchelRivadeneyra","year":"2014","unstructured":"AlmanchelRivadeneyra M, Pellicer Franco C, Mu\u00f1oz Contreras C et al (2014) CP-006 effectiveness and safety of belimumab for systemic lupus erythematosus. Eur J Hosp Pharm 21(Suppl 1):A2.3-A3. https:\/\/doi.org\/10.1136\/ejhpharm-2013-000436.6","journal-title":"Eur J Hosp Pharm"},{"issue":"Suppl 2","key":"6287_CR42","doi-asserted-by":"publisher","first-page":"985.2","DOI":"10.1136\/annrheumdis-2014-eular.5447","volume":"73","author":"P Brito Zeron","year":"2014","unstructured":"Brito Zeron P, Caminal-Montero L, Chamorro A et al (2014) AB0542 blocking the human B lymphocyte stimulator molecule (BLYS) using a monoclonal antibody (belimumab) in systemic lupus erythematosus: first results in real-life Spanish patients with refractory disease (Biogeas-Semi Registry). Ann Rheum Dis 73(Suppl 2):985.2-985. https:\/\/doi.org\/10.1136\/annrheumdis-2014-eular.5447","journal-title":"Ann Rheum Dis"},{"key":"6287_CR43","doi-asserted-by":"publisher","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A et al (2019) Update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases. Ann Rheum Dis 78(6):736\u2013745. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.3117","DOI":"10.1136\/annrheumdis-2019-eular.3117"},{"key":"6287_CR44","doi-asserted-by":"crossref","unstructured":"Zonana-Nacach A, Barr SG, Magder LS, Petri M (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43(8):1801\u20138. https:\/\/pubmed.ncbi.nlm.nih.gov\/10943870\/","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O"},{"issue":"3","key":"6287_CR45","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/annrheumdis-2018-214043","volume":"78","author":"MB Urowitz","year":"2019","unstructured":"Urowitz MB, Ohsfeldt RL, Wielage RC, Kelton KA, Asukai Y, Ramachandran S (2019) Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. Ann Rheum Dis 78(3):372\u2013379. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214043","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"6287_CR46","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O et al (2011) A phase III randomized placebo-controlled study of Belimumab a monoclonal antibody that inhibits B lymphocyte stimulator in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918\u201330. https:\/\/doi.org\/10.1002\/art.30613","journal-title":"Arthritis Rheum"},{"key":"6287_CR47","doi-asserted-by":"publisher","unstructured":"Iaccarino L, Saccon F, Mathieu A et al (2019) FRI0199 effectiveness and safety of belimumab in patients with active systemic lupus erythematosus: results from a large, nationwide, multicentric study. BMJ :778\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.3635","DOI":"10.1136\/annrheumdis-2019-eular.3635"},{"issue":"2","key":"6287_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/03009742.2015.1074277","volume":"45","author":"V Furer","year":"2016","unstructured":"Furer V, Zisman D, Pokroy-Shapira E, Molad Y, Elkayam O, Paran D (2016) Systemic lupus erythematosus exacerbation following cessation of belimumab treatment. Scand J Rheumatol 45(2):103\u2013106","journal-title":"Scand J Rheumatol"},{"key":"6287_CR49","unstructured":"Bae S, Dimelow R, Ji B, Kurrasch R, Muzaffar S, Punwaney R, Roth D, Stober P, Song Y, Xie W ZF (2019) Results of the open-label, non-randomized 52-week study to evaluate treatment holidays and rebound phenomenon after treatment with belimumab in patients with SLE. Arthritis Rheumatol. https:\/\/acrabstracts.org\/abstract\/results-of-the-open-label-non-randomized-52-week-study-to-evaluate-treatment-holidays-and-rebound-phenomenon-after-treatment-with-Belimumab-in-patients-with-sle\/"},{"issue":"6","key":"6287_CR50","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/art.40439","volume":"70","author":"RA Furie","year":"2018","unstructured":"Furie RA, Wallace DJ, Aranow C et al (2018) Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: a continuation of a seventy-six\u2013week phase III parent study in the United States. Arthritis Rheumatol 70(6):868\u201377. https:\/\/doi.org\/10.1002\/art.40439","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"6287_CR51","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","volume":"71","author":"RF Van Vollenhoven","year":"2012","unstructured":"Van Vollenhoven RF, Petri MA, Cervera R et al (2012) Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 71(8):1343\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200937","journal-title":"Ann Rheum Dis"},{"key":"6287_CR52","doi-asserted-by":"crossref","unstructured":"Cevey M, Calvo-Al\u00e9n J, Crespo C, Robles-Marhuenda A, Smolen L, Cort\u00e9s-Hern\u00e1ndez J (2019) Budget impact analysis of subcutaneous belimumab in patients with systemic lupus erythematosus in Spain. Clin Outcomes Res Volume 11:757\u201365. https:\/\/www.dovepress.com\/budget-impact-analysis-of-subcutaneous-Belimumab-in-patients-with-syst-peer-reviewed-article-CEOR","DOI":"10.2147\/CEOR.S218464"},{"key":"6287_CR53","doi-asserted-by":"publisher","first-page":"102827","DOI":"10.1016\/j.jaut.2022.102827","volume":"129","author":"M Fabris","year":"2022","unstructured":"Fabris M, De Marchi G, Domenis R, Caponnetto F, Guella S, Dal Secco C, Cabas N, De Vita S, Beltrami AP, Curcio F, Quartuccio L (2022) High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients. J Autoimmun 129:102827. https:\/\/doi.org\/10.1016\/j.jaut.2022.102827","journal-title":"J Autoimmun"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06287-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06287-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06287-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T09:15:26Z","timestamp":1665738926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06287-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["6287"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06287-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,23]]},"assertion":[{"value":"28 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Authors have not been paid for this publication. AZG and FJM are GSK employees. NBR was a GSK employee. FJM declares employment and stock ownership. CRE and MJGV declared no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}